





Untargeted Metabolomics Profiling of an 80.5 km
Simulated Treadmill Ultramarathon
Christopher C. F. Howe 1, Ahmed Alshehri 2, David Muggeridge 3, Alexander B. Mullen 2,
Marie Boyd 2, Owen Spendiff 1, Hannah J. Moir 1 ID and David G. Watson 2,* ID
1 Applied & Human Sciences, School of Life Sciences, Pharmacy & Chemistry, Kingston University London,
Kingston upon Thames KT1 2EE, UK; C.Howe@kingston.ac.uk (C.C.F.H.); O.Spendiff@kingston.ac.uk (O.S.);
H.Moir@kingston.ac.uk (H.J.M.)
2 Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde,
The John Arbuthnott Building, 161 Cathedral Street, Glasgow G4 0RE, UK;
ahmed.alshehri@strath.ac.uk (A.A.); a.mullen@strath.ac.uk (A.B.M.); marie.boyd@strath.ac.uk (M.B.)
3 School of Psychological & Health Sciences, University of Strathclyde, Glasgow G4 0RE, UK;
david.muggeridge@strath.ac.uk
* Correspondence: d.g.watson@strath.ac.uk; Tel.: +44-141-54-82-651
Received: 7 January 2018; Accepted: 8 February 2018; Published: 13 February 2018
Abstract: Metabolomic profiling of nine trained ultramarathon runners completing an 80.5 km
self-paced treadmill-based time trial was carried out. Plasma samples were obtained from venous
whole blood, collected at rest and on completion of the distance (post-80.5 km). The samples
were analyzed by using high-resolution mass spectrometry in combination with both hydrophilic
interaction (HILIC) and reversed phase (RP) chromatography. The extracted putatively identified
features were modeled using Simca P 14.1 software (Umetrics, Umea, Sweden). A large number
of amino acids decreased post-80.5 km and fatty acid metabolism was affected with an increase in
the formation of medium-chain unsaturated and partially oxidized fatty acids and conjugates of
fatty acids with carnitines. A possible explanation for the complex pattern of medium-chain and
oxidized fatty acids formed is that the prolonged exercise provoked the proliferation of peroxisomes.
The peroxisomes may provide a readily utilizable form of energy through formation of acetyl
carnitine and other acyl carnitines for export to mitochondria in the muscles; and secondly may
serve to regulate the levels of oxidized metabolites of long-chain fatty acids. This is the first study to
provide evidence of the metabolic profile in response to prolonged ultramarathon running using an
untargeted approach. The findings provide an insight to the effects of ultramarathon running on the
metabolic specificities and alterations that may demonstrate cardio-protective effects.
Keywords: ultramarathon running; metabolomics; high resolution mass spectrometry; acyl carnitines;
oxidized fatty acids
1. Introduction
There has been an upward trend in life expectancy over the past few years in developed countries,
but lifestyle risks still pose real challenges to longevity. These risks factors include obesity, unhealthy
diet, cigarette smoking, sedentary lifestyle, and alcohol consumption [1]. Regular physical activity,
coupled with a healthy balanced diet and moderate to no alcohol consumption, can significantly
decrease the impact of these risk factors resulting in an increased life expectancy [2]. For instance, it has
been reported that regular exercise attenuates sarcopenia and promotes cardiovascular health [3–5] as
well as being prescribed for individuals with diabetes [6], obesity, and mild to moderate depression [5].
Moreover, it has been reported that incidences of hypertension, hypercholesterolemia, and diabetes
decrease with the frequency of participation in marathons independent of the total distance run
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annually, but this might be due to longer training runs or genetic and innate differences between
endurance trained marathon runners and those who are not [7]. It has been reported that compared to
the general population ultra-endurance athletes have missed fewer work/school days through illness
and injury and have overall lower incidences of chronic disease [8]. Although it has been suggested
that sustained exercise such as ultra-marathon running may cause adverse cardiovascular effects [9],
some studies suggest that chronic ultra-endurance training may attenuate biological ageing [10,11].
The rising popularity of ultramarathon running over the past few years has seen non-professional
runners striving for bigger and tougher extreme physical challenges [8,12,13]. An ultramarathon is
considered anything beyond a traditional marathon distance (42.2 km) with the majority of races
being 80.5 km or more [12,14–17]. Of particular interest, is the increase in participation of runners
with less than three years of regular running experience (25%) from the point of taking part in their
first ultra-distance event [8]. Such extreme endurance events place a great deal of physiological
and psychological demands on the body and with this increase in participation, and though it
is perceived participants of such endurances, appear fit and healthy, there have been occasional
reports of severe complications following ultra-endurance exercise and concern of harmful effects on
health such as cardiac damage [9,18]. Ultramarathon runners place themselves at the risk of extreme
fatigue, exhaustion and test their own personal limits [19]. Therefore, understanding the effects and
implications of ultramarathon events is needed and the ultramarathon runners profile provides a
unique model to investigate the physiological responses to prolonged physical exertion.
Ultra–endurance athletes push themselves beyond ordinary limits [20], with prolonged
endurance exercise, eliciting extreme metabolic stress, inducing metabolic changes such as metabolite
accumulation [21] muscle glycogen depletion [22,23], and fat oxidation [24]. Currently, data on the
metabolomic alterations that occur during exercise are still limited. A previous study of healthy adults
subjected to submaximal exercise showed significant increases in a range of purine metabolites and
several acyl carnitines [25]. Understanding of such metabolic changes could enable the elucidation of
individual’s ability to maintain peak performance and physiological function [20].
When looking at the traditional marathon, physical performance can be affected by gender [26–28],
age [29], lifestyle, and body mass index (BMI) [30], through differences in physiological (e.g., muscle
strength, oxygen carrying capacity) and morphological (e.g., percentage of body fat, muscle mass)
characteristics of an individual [31]. However, the amount of exercise optimal for a given individual
remains unknown due to absence of definitive data on the molecular mechanisms underlying exercise
in relation to health, particularly regarding ultra-endurance distances. Therefore, investigation of
the metabolomic effect of exercise on the human metabolome could provide insights into phenotypic
responses, permit development of personalized training regimes based on initial metabolic status of
an individual [32], and yield vital diagnostic and prognostic biomarkers for use by physicians in the
management of cardiovascular and other related diseases [33].
The aim of the current study was to analyze the change in metabolic profile of trained
ultramarathon runners in response to an 80.5 km simulated treadmill ultramarathon in a controlled
laboratory environment. Plasma samples were analyzed for their metabolomic profiles to determine
the metabolic changes due to extreme exercise in order gain some insight into how metabolism is
adapted for endurance performance.
2. Results
2.1. Physiological Response to the Ultramarathon
Nine male participant runners (mean age 34± 7 years, .VO2max 61.6± 4.3 mL/min/kg) completed
the time trial in 9 h:17 min:18 s ± 1 h:18 min:24 s. The fastest time to complete was 7 h:4 min:9 s and
the longest time to complete was 10 h:37 min:37 s with an average
.
VO2max as percentage of maximum
(64.5 ± 3.8%).
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2.2. Variation of Metabolic Profile with Exercise
Principal component analysis (PCA) of the HILIC data showed clear separation between the
pre- and post-80.5 km samples (Figure 1). The data set of 542 polar metabolites was filtered by
excluding 96 metabolites which had relative standard deviation (RSD) values >20% within the pooled
samples. Figure 1 shows a clear separation of the pre- and post 80.5 km samples according to principial
component analysis (PCA) based on 446 metabolites annotated to Metabolomics Standards Initiative
(MSI) levels 2/1 [34], where level 2 consisted of mass matching to <3 ppm to a metabolite in the
database and level 1 consisted of mass matching to <3 ppm and a retention time corresponding to a
standard. The pooled samples (P) clustered in the middle of the plot indicating reasonable technical
stability throughout the run (Figure 1, P1–6) but they indicated some drift which may account to some
of the variation between individuals. There was a technical problem with one of the post-80.5 km
samples which was removed from the plot (total post 80.5 km n = 8). The model explained 82.6% of
the variation in the data in principal component analysis score plot (PC1 and PC2). From Figure 1
it can be seen that ultramarathon running has a strong impact on the levels of polar metabolites in
plasma although there is considerable variation between with individuals with regard to their response.
The data for the 500 lipophilic metabolites was filtered by excluding 200 metabolites which had RSD
>20% in the pooled samples. The PCA model shown in Figure 2 is based on 300 metabolites annotated
to MSI level 2. The model explains 80.7% of the variation in the data in two components. It is not
as strong as the model based on polar metabolites and pre-80.5 km samples C2 and E2 are outliers
taken from the same individual. Figure S1 shows that there was no separation between two baseline
samples one having been taken prior to the day of the run for a model based on the polar metabolites.
Figure S2 shows that there was no clear separation between the two sets of baseline samples although
again sample B1 is an outlier for the same individual who produced outliers in Figure 2. Figures S3–S80
show comparisons of the absolute response in pre-80.5 km and post-80.5 km for selected metabolites
using bar graphs along with comparison of these metabolites in baseline and pre-80.5 km. It is clear
that the marked shifts in metabolite levels between the pre-80.5 km and post-80.5 km samples are
absent when baseline and pre-80.5 km samples are compared. The only metabolites that show some
change between baseline and post-80.5 km are bile acids. We observed previously that bile acids show
some diurnal variation [25].
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2.3. Univariate Comparisons
As can be seen in Table 1 there were a very large number of metabolic changes resulting from
the bout of ultramarathon running, with many amino acids decreasing in abundance while there
were increases in the levels of many acylcarnitines, fatty acids and oxidized fatty acids. In many
cases, the findings are significant for the comparison of the pre- and post-80.5 km sa ples and a false
discovery rate (FDR) test confirmed the significance to all metabolites with p < 0.05 [35]. In order to
gain a comprehensive overview, analysis was also carried out by RP chromatography, which as useful
for getting a clearer picture of the lipophilic compounds in plasma including long-chain acylcarnitines,
fatty acids and oxidized fatty acids. The results from the RP analysis of acylcarnitines, fatty acids and
oxidized fatty acids are also shown in Table 1. The RP mode was better for these classes of compounds
since in HILIC mode they all eluted close to the column void volume. Table S1 shows the etabolites,
which were matched against a standard. Table S2 shows a list of the standards that were run in five
standard mixtures plus a mixture of free fatty acids derived from two fixed oils, olive oil and cod
liver oil.
Table 1. All the metabolites affected significantly by the ultramarathon time trial (p value < 0.05) or
fold change >2 or <0.5. * atches retention ti e of standard. ‡ ata fro runs on ACE C4 column
otherwise run on the pHILIC column. A separ te list of metabolites identified at MSI level 1 is given in
Table S1.
Mode Mass RT (min) Metabolite Ratio[Post-80.5 km/Pre-80.5 km] p-Value
Amino acids and their metabolites
+ 75.032 15.4 * Glycine 0.510 <0.001
+ 89.048 14.4 * Alanine 0.603 0.012
+ 103.063 13.4 * 3-Amino-isobutanoate 0.392 <0.001
+ 105.043 15.7 * Serine 0.512 <0.001
+ 111.032 9.5 Pyrrole-2-carboxylate 0.413 <0.001
115.063 12.4 * li 0.420 <0.0 1
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Table 1. Cont.
Mode Mass RT (min) Metabolite Ratio[Post-80.5 km/Pre-80.5 km] p-Value
Amino acids and their metabolites
+ 116.047 1.7 Oxopentanoic acid 0.819 <0.001
+ 117.054 15.5 Guanidinoacetate 0.627 0.001
+ 117.079 12.1 * Valine 0.447 <0.001
+ 117.079 10.8 * Betaine 0.505 <0.001
- 118.063 1.8 Hydroxypentanoate 1.393 <0.001
+ 119.058 14.4 * Threonine 0.217 <0.001
+ 125.015 15.4 * Taurine 0.565 0.001
+ 129.043 14.1 5-Oxoproline 0.352 <0.001
+ 131.058 14.1 Hydroxyproline 0.361 <0.005
+ 131.095 10.3 * Leucine 0.455 <0.001
+ 131.095 10.8 * Isoleucine 0.430 <0.001
+ 132.079 2.1 Hydroxyhexanoic acid ‡ 2.237 0.004
+ 132.053 15.2 * Asparagine 0.465 <0.001
+ 132.090 22.4 * Ornithine 0.545 0.003
+ 138.043 8.8 * Urocanate 0.626 0.019
+ 146.069 14.8 * Glutamine 0.710 <0.001
+ 146.106 23.8 * Lysine 0.369 <0.006
+ 147.053 11.2 * Glutamate 0.528 <0.001
+ 149.051 11.2 * Methionine 0.609 <0.003
- 154.038 11.7 Imidazol-5-yl-pyruvate 0.469 <0.001
- 159.068 8.1 Indole-3-acetaldehyde 0.432 0.001
+ 161.069 9.9 O-Acetylhomoserine 0.524 <0.001
+ 174.112 25.4 * Arginine 0.387 <0.003
+ 175.096 15.6 * Citrulline 0.673 0.047
+ 181.074 12.8 * Tyrosine 0.761 0.016
- 182.058 9.4 Hydroxyphenyllactate 0.541 0.002
+ 188.116 16.2 N6-Acetyl-L-lysine 0.233 0.054
+ 189.043 6.4 Kynurenate 2.322 0.001
+ 204.090 11.1 * L-Tryptophan 0.539 <0.001
+ 208.085 10.2 Formylhydroxykynurenamine 0.668 0.004
- 219.053 4.9 Hydroxyindolepyruvate 5.131 0.010
Acylcarnitines
+ 204.123 10.3 * Acetylcarnitine 3.353 <0.001
218.138 9.1 Propanoylcarnitine 1.420 0.042
+ 232.154 7.9 Butanoylcarnitine 1.775 0.010
+ 258.170 2.1 Hexenoylcarnitine ‡ 6.350 0.002
+ 260.185 2.4 * Hexanoylcarnitine isomer ‡ 9.640 0.011
260.185 2.9 Hexanoylcarnitine isomer ‡ 13.091 0.045
+ 274.201 3.0 Heptanoylcarnitine ‡ 5.685 0.013
+ 286.201 3.6 Octenoylcarnitine ‡ 6.009 0.003
+ 286.201 3.1 Octenoylcarnitine ‡ 5.184 0.001
+ 288.217 4.2 * Octanoylcarnitine ‡ 7.119 0.004
302.232 4.8 Nonanoykcarnitine ‡ 14.587 0.001
+ 312.217 4.7 Decadienoylcarnitine ‡ 7.016 0.001
+ 312.217 3.7 Decadienoylcarnitine ‡ 16.727 0.102
+ 314.232 6.2 Decenoylcarnitine ‡ 7.186 0.039
+ 314.232 5.8 Decenoylcarnitine ‡ 6.285 0.004
+ 316.248 7.1 * Decanoylcarnitine ‡ 5.017 0.005
330.227 4.4 Keto-decanoylcarnitine ‡ 13.121 0.000
+ 330.227 3.0 Keto-decanoylcarnitine ‡ 7.719 0.003
330.263 8.3 Dimethylnonanoylcarnitine ‡ 11.088 0.002
+ 342.264 9.4 Dodecenoylcarnitine ‡ 6.439 0.089
+ 342.264 9.1 * Dodecenoylcarnitine ‡ 8.849 0.004
+ 360.274 6.0 Hydroxydodecanoylcarnitine ‡ 4.825 0.003
+ 368.279 10.8 Tetradecadiencarnitine isomer ‡ 5.659 0.022
+ 368.279 9.5 Tetradecadiencarnitine isomer ‡ 24.743 0.012
+ 368.279 9.9 Tetradecadiencarnitine isomer ‡ 19.098 0.055
+ 368.279 11.9 Tetradecadiencarnitine isomer ‡ 9.195 0.031
+ 370.295 13.3 Tetradecenoylcarnitine isomer ‡ 16.422 0.070
+ 370.295 12.9 Tetradecenoylcarnitine isomer ‡ 9.253 0.004
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Table 1. Cont.
Mode Mass RT (min) Metabolite Ratio[Post-80.5 km/Pre-80.5 km] p-Value
Acylcarnitines
+ 372.310 15.3 * Tetradecanoylcarnitine ‡ 18.265 0.007
+ 384.274 6.6 Hydroxytetradecadiencarnitine ‡ 11.908 0.001
+ 386.290 8.1 Hydroxytetradecenoylcarnitine ‡ 6.193 0.007
+ 386.290 8.9 Hydroxytetradecenoylcarnitine ‡ 27.813 0.003
+ 388.305 9.4 Hydroxymyristoylcarnitine ‡ 4.245 0.006
+ 396.310 15.2 Hexadecadienoylcarnitine ‡ 90.958 0.149
+ 396.311 14.5 Hexadecadienoylcarnitine ‡ 17.816 0.016
+ 398.326 17.1 Hexadecenoylcarnitine ‡ 14.097 0.011
+ 400.342 19.7 Palmitoylcarnitine ‡ 4.618 0.089
+ 412.305 9.3 Hydroxyhexadecadienoylcarnitine ‡ 6.590 0.003
+ 414.321 11.1 Hydroxyhexadecenoylcarnitine ‡ 35.292 0.003
+ 424.342 18.6 Octadecadienoylcarnitine ‡ 3.955 0.048
+ 424.342 19.3 Octadecadienoylcarnitine ‡ 6.043 0.121
+ 430.316 8.1 Hexadecanedioicacidmonocarnitineester ‡ 114475.436 0.015
Fatty acids
- 172.147 10.0 Decanoic acid ‡ 1.909 0.034
- 196.146 10.1 Dodecadienoic acid ‡ 5.989 0.001
- 200.178 13.4 Dodecanoic acid 4.342 0.009
- 202.120 3.2 Decanedioic acid ‡ 6.045 0.004
- 210.126 9.3 Hydroxydodecatrienoic acid ‡ 4.709 0.001
- 212.178 13.3 Tridecenoic acid ‡ 13.224 0.006
- 224.178 13.2 Tetradecadienoic acid ‡ 10.003 0.013
- 226.193 14.5 Tetradecenoic acid isomer ‡ 25.065 0.004
- 226.193 14.9 Tetradecenoic acid isomer ‡ 14.409 0.020
- 230.152 5.0 Dodecanedioic acid ‡ 9.432 0.014
- 240.173 8.2 Hydroxytetradecadienoic acid ‡ 11.109 0.002
- 240.209 16.5 Pentadecenoic acid ‡ 3.192 0.007
- 242.188 11.4 Hydroxytetradecadienoic acid ‡ 4.066 0.001
- 244.204 8.2 Hydroxytetradecanoic acid isomer ‡ 11.109 0.002
- 244.204 9.3 Hydroxytetradecanoic acid isomer ‡ 3.581 0.000
- 252.209 15.8 * Hexadecadienoicacid isomer ‡ 10.174 0.059
- 252.209 16.3 * Hexadecadienoicacid isomer ‡ 13.108 0.041
- 254.224 17.5 * Palmitoleic acid ‡ 38.719 0.006
- 258.183 7.4 Tetradecanedioic acid ‡ 7.206 0.006
- 266.188 13.6 Hydroxyhexadecatrienoic acid ‡ 8.977 0.014
- 268.204 11.3 Hydroxyhexadecadienoic acid 3.355 0.007
- 268.240 18.9 Heptadecenoic acid ‡ 29.923 0.004
- 270.220 12.1 Hydroxyhexadecenoic acid isomer ‡ 3.553 0.004
- 270.220 17.5 Hydroxyhexadecenoic acid ‡ 8.969 0.001
- 272.235 11.3 Hydroxyhexadecanoic acid ‡ 8.969 0.001
- 276.209 15.6 * Octadecatetraenoic acid ‡ 10.190 0.067
- 278.225 16.9 * Linolenic acid ‡ 8.511 0.003
- 280.240 18.4 * Linoleic acid ‡ 5.769 0.008
- 282.256 20.3 * Oleic acid ‡ 6.231 0.000
- 284.199 9.1 Dihydroxyhexadecadienoic acid ‡ 2.897 0.001
- 286.214 10.5 Dihydroxyhexdecenoic acid ‡ 16.426 0.001
- 296.235 14.0 Hydroxyoctadecadienoic acid ‡ 3.145 0.024
- 300.266 14.3 Hydroxyoctdecanoic acid ‡ 6.618 0.015
- 316.261 9.8 Dihydroxyoctadecanoic acid ‡ 4.040 0.002
- 327.241 7.0 Nitrooctadecenoic acid ‡ 10.453 <0.001
- 328.240 18.3 * Docosahexaenoicacid ‡ 4.266 0.022
- 330.256 19.0 * Docosapentaenoic acid ‡ 9.179 0.003
- 332.272 20.5 Docosatetraenoic acid ‡ 14.588 0.002
Steroids
- 362.209 4.5 Hydrocortisone 1.787 0.014
- 364.225 5.0 Urocortisone 3.243 0.003
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Table 1. Cont.
Mode Mass RT (min) Metabolite Ratio[Post-80.5 km/Pre-80.5 km] p-Value
Steroids
- 376.298 3.9 Hydroxycholanate 0.315 0.004
- 392.293 4.3 Deoxycholanoic acid 0.361 0.026
- 449.314 4.3 Chenodeoxyglycocholate 0.162 <0.001
- 465.309 4.9 * Glycocholate 0.174 0.003
- 515.291 4.5 Taurocholate 0.275 0.039
- 568.324 7.3 Chenodeoxycholic acid glucuronide 0.311 <0.001
- 612.387 4.5 Cholestane—tetrol-glucuronide 0.443 0.001
Miscellaneous
+ 136.039 9.8 * Hypoxanthine 1.917 0.003
- 244.069 9.5 * Uridine 0.420 <0.001
- 244.070 11.7 Pseudouridine 0.416 <0.001
+ 136.064 23.7 * 1-Methylnicotinamide 0.226 0.090
- 164.069 11.8 Rhamnose 0.348 <0.001
+ 179.079 10.8 Galactosamine 0.181 <0.001
- 180.064 14.1 Hexose 0.447 <0.001
+ 214.132 9.4 Dethiobiotin 1.517 0.002
- 416.366 3.4 gamma-Tocopherol 0.529 <0.001
- 430.381 3.4 Alpha-Tocopherol 0.509 <0.001
3. Discussion
The aim of the current study was to determine an untargeted metabolic response to an 80.5 km
treadmill-based ultramarathon. The observed clear separation between baseline samples (pre 80.5 km)
and samples taken immediately on completion of the distance (post 80.5 km) with the use of a
PCA model demonstrated that there were significant metabolic changes induced by the extreme
exercise of ultramarathon running. For some metabolites, the changes were very large and were
highly significant when the two cohorts were compared (Table 1). The major changes concern
fatty acid metabolism, with a large elevation in acylcarnitine levels in plasma for a wide range
of these compounds. The impact of exercise on carnitines has been observed before in a number
of studies [36–40]. A possible explanation is that the carnitines reflect mitochondrial fatty acid
oxidation as an energy source under the impact of exercise. This is of interest since acylcarnitine
accumulation has been identified during prolonged fasting and similar increased demands on stored
energy [39] would be expected in an ultra-marathon event. The elevations in fatty acids are supported
by previous findings [41] where it was demonstrated that elevated rates of fat oxidation and ability
to maintain glycogen concentrations were found in highly trained ultra-endurance athletes. It was
shown in the metabolic response to a 24 h ultra-marathon run that there was an increased lipid
profile with substrate utilization shift towards fat oxidation [24] suggesting reduction in cardiovascular
disease (CVD) risk [42]. More recently it has been hypothesized that acyl carnitines have neuroactive
properties that can regulate exertion via interaction with the neurons regulating muscle activity [40].
Less frequently studied are the products of fatty acid oxidation that accumulate in plasma during
exercise [43,44]. Many oxidized fatty acids have potent effects on blood vessels promoting either
vasodilation or vasoconstriction [45]. As observed (Table 1 and Figure S81) there is a complex mixture
of fatty acids all of which are greatly elevated in plasma following exercise. The oxidation products
of linoleic acid 9-hydroxylinoleic acid and 13-hydroxylinoleic acid have been proposed as markers
of oxidative stress following exercise and several isomers of hydroxylinoleic acids were elevated
in the post-80.5 km samples in comparison to baseline (Table 1). This supports the findings of
previous studies that have demonstrated ultra-endurance exercise-induced reactive oxygen species
(ROS) production [46]. Figure S81 shows extracted ion chromatograms for the pre- and post- levels of
oxidized octadecadienoic acid. The range of oxidized fatty acids elevated post-exercise is extensive
and the increases very marked (Table 1), therefore the elevation of hydroxyoctadecadienoicacids is
not exclusive and there are many other hydroxy acids which are elevated post-exercise plus some
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dioic acids. Whether or not these acids also have biological activities is unknown, as is the precise
reason for their elevation. When the heat map (Figure 3) is considered it is evident that many of the
oxidized fatty acids, although elevated (Table 1), are of relatively low abundance. It has been suggested
that oxidized acids are a marker of oxidative stress [43,44] but it might be expected that other readily
oxidized acids present in plasma, such as eicosapentaenoic acid (EPA), might also be oxidized in the
same way, but despite EPA being relatively abundant in the plasma, no peaks for hydroxy EPAs can be
seen. Therefore, it is possible that there is some biological mechanism that keeps oxidation products
of EPA at low levels since many of these metabolites have potent anti-inflammatory and vasoactive
effects [47]. Although oxidative stress was not measured in the current study, previous studies have
demonstrated ultra-marathon running induces reactive oxygen species (ROS) production and markers
of oxidative damage [48] and this warrants further investigation.
Given the wide range of unsaturated fatty acids and hydroxylated fatty acids (Table 1) it would
seem likely that these compounds arise from peroxisomal metabolism and this might provide a
protective mechanism for ensuring that the levels of oxidized long-chain unsaturated acids are
kept at low levels. Peroxisomes are known to be responsible for degrading prostaglandins [49].
Unlike mitochondrial beta-oxidation of fatty acids, peroxisomal beta-oxidation of fatty acids does
not necessarily go to completion and acids may only be shortened by 3–4 cycles of 2 carbon chain
shortening [49] yielding a molecule of acetyl CoA/acetyl carnitine at each cycle. For instance, it might
be significant that hexadecadienoic acid, tetradecadienoic acid and dodecadiencoic acid are all elevated,
these are not abundant naturally occurring fatty acids, but they are all products of chain shortening of
linoleic acid via beta-oxidation [49]. Similarly, hexdecatrienoic acid could arise from chain shortening
of linolenic acid via one beta-oxidation step. The reason for the metabolism pausing when a double
bond is encountered within the fatty acid chain is that at this point further metabolism requires the
commitment of nicotinamide adenine dinucleotide phosphate, (NADPH) in the reduction of the double
bond before further chain shortening can occur [49]. Under conditions of aerobic stress there will be
generally a high requirement for NADPH in countering oxidative stress; it is required for instance
in the recycling of glutathione disulfide back to glutathione. The elevated levels of acylcarnitines
are consistent with increased beta-oxidation of fatty acids by peroxisomes since they are the major
product exported out of peroxisomes resulting from fatty acid beta-oxidation. It has previously been
demonstrated that physical exercise increases peroxisome levels in rat heart [50]. Acetyl carnitine is
readily utilized by mitochondria as a source of acetyl CoA, which can be metabolized via the Krebs
cycle. The major question with regard to carnitines is; are they waste products or utilizable as substrates
for further oxidation? Conversion of acylCoAs to acylcarnitines is necessary in order to preserve free
levels of CoA within the mitochondria [51]. The heat map (Figure 3) indicates in terms of absolute
abundance that the common dietary fatty acids are much higher in plasma than the unusual acids,
which are promoted by exercise observed in the current study. Thus, it seems probable that medium
chain length unsaturated fatty acids are minor metabolites due to partial metabolism of long-chain
unsaturated fatty acids by peroxisomes providing an additional source of acetylcarnitine for export
to mitochondria. The heat map (Figure 4) shows the relative abundance of the 40 most abundant
acyl carnitines in plasma. Acetyl carnitine is highly abundant while the carnitines corresponding
to the medium-chain fatty acids are of much lower abundance. Although the levels of some acyl
carnitines rise in urine post-exercise they do not increase to the same extent as the plasma levels in the
current study and no increase in post-exercise urinary acetyl carnitine was observed previously [25].
This suggests that the carnitines may be produced for utilization as energy substrates. Conversion of
free fatty acids to acyl CoAs requires the investment of a molecule of adenosine triphosphate (ATP).
However, acyl carnitines are an activated form of fatty acid substrate and are convertible into acyl
CoAs without the investment of ATP in creating the thioester bond and thus they can be taken up into
mitochondria and further metabolized [51,52].
Metabolites 2018, 8, 14 9 of 17
Metabolites 2018, 8, x  8 of 16 
 
 
Figure 3. Heat map showing the relative abundance of the 30 most abundant fatty acids in plasma for 
the pre- and post-80.5 km samples and two post-exercise samples. Red = highest value (3.93 × 107), 
Yellow = 1 × 105 and blue = 5 × 103. Rt = retention time. 
  
Figure 3. Heat map showing the relative abundance of the 30 most abundant fatty acids in plasma for
the pre- and post-80.5 km samples and two post-exercise samples. Red = highest value (3.93 × 107),
Yellow = 1 × 105 and blue = 5 × 103. Rt = retention time.
Metabolites 2018, 8, 14 10 of 17
Metabolites 2018, 8, x  10 of 16 
 
 
Figure 4. Changes in the 40 most abundant acylcarnitines in plasma following an ultramarathon 
analyzed by RP method for the pre- and post-80.5 km samples and two post-exercise samples. Red = 
highest value (2.6 × 107), Yellow = 5 × 104 and blue = 5 × 103. 
The levels of almost all the amino acids in the plasma samples decreased significantly. The fall 
in the amino acids used in protein biosynthesis might be due to an increase in protein biosynthesis 
during exercise, which was observed to occur [54,55]. Hydrocortisone is responsible for maintaining 
a homeostasis under stress conditions, in this study both hydrocortisone and its metabolite 
urocortisone are increased and this was observed to occur in previous studies [56,57]. The most 
studied metabolites with regard to the effect of exercise and the determination of fitness are 
metabolites in the purine pathway such as hypoxanthine and inosine; a marked change in levels of 
hypoxanthine was observed in the present study. The re-uptake of hypoxanthine into muscle was 
observed to be more efficient in highly trained individuals [58] and the elevation of hypoxanthine in 
plasma during exercise is less marked than we observed in urine samples taken post-exercise [25]. 
However, since the athletes in the current study were trained, it might be expected that their 
metabolism be geared to conserving purines [59]. Future research is also warranted to determine the 
Figure 4. Changes in the 40 most abundant acylcarnitines in plasma following an ultramarathon
analyzed by RP method for the pre- and post-80.5 km samples and two post-exercise samples. Red =
highest value (2.6 × 107), Yellow = 5 × 104 and blue = 5 × 103.
Therefore, the pattern of fatty acids and carnitines observed in the current study points strongly
towards a large increase in peroxisomal metabolism. For example, a widely studied substrate of
peroxisomal metabolism is phytanic acid, which is present in dairy products [50]. This compound
undergoes α-oxidation in the peroxisomes producing pristanic acid, which is then further metabolized
by the peroxisomes yielding propanolyl CoA (carnitine) and dimethyl nonanoyl CoA (undecanoyl
carnitine) after six cycles of beta oxidation. Both of these carnitines are elevated in the post-80.5 km
samples and provide potential substrates for mitochondrial metabolism in the muscles.
The increased activity of the peroxisomes is further underlined by elevated levels of some dioic
acids (Table 1), which are also only produced by peroxisomes. The hypothesis that the metabolite
patterns are consistent with peroxisomal proliferation is consistent with our earlier observations where
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it was proposed that exercise increased the proliferation of peroxisome proliferator-activated receptor
(PPAR)-γ ligands in plasma [53]. From the current study, these ligands might well be long-chain
unsaturated fatty acids, which are substrates for peroxisomal metabolism as discussed above.
The levels of almost all the amino acids in the plasma samples decreased significantly. The fall
in the amino acids used in protein biosynthesis might be due to an increase in protein biosynthesis
during exercise, which was observed to occur [54,55]. Hydrocortisone is responsible for maintaining a
homeostasis under stress conditions, in this study both hydrocortisone and its metabolite urocortisone
are increased and this was observed to occur in previous studies [56,57]. The most studied metabolites
with regard to the effect of exercise and the determination of fitness are metabolites in the purine
pathway such as hypoxanthine and inosine; a marked change in levels of hypoxanthine was observed
in the present study. The re-uptake of hypoxanthine into muscle was observed to be more efficient in
highly trained individuals [58] and the elevation of hypoxanthine in plasma during exercise is less
marked than we observed in urine samples taken post-exercise [25]. However, since the athletes in
the current study were trained, it might be expected that their metabolism be geared to conserving
purines [59]. Future research is also warranted to determine the long-term adaptations to ultramarathon
training. Changes in uridine following exercise have been observed previously and most often increases
have been observed, in the current case there was a marked decrease [60]. Changes in tocopherols have
also been observed previously in exercise studies and γ-tocopherol has been correlated to
.
VO2max
level [37]. In summary, many amino acids were lowered in plasma post-exercise but the clearest impact
of endurance exercise is on fatty acid metabolism but with respect to formation of medium-chain
unsaturated and partially oxidized fatty acids and conjugates of fatty acids with carnitines. Many of
these metabolites were increased several fold. The most likely explanation for the complex pattern of
medium-chain and oxidized fatty acids formed is that the prolonged exercise provoked the proliferation
of peroxisomes. The peroxisomes may serve two functions, one of providing a readily utilizable form
of energy through formation of acetyl carnitine and other acyl carnitines for export to mitochondria in
the muscles; which can utilize these substrates without investment of the adenosine triphosphate (ATP)
required to conjugate free fatty acids to acetyl-Coenzyme-A. Secondly the peroxisomes may serve to
regulate the levels of oxidized metabolites of long-chain fatty acids since many of these metabolites
can provoke biological responses such as vasoconstriction or have pro-inflammatory activity.
To the authors’ knowledge, this is the first study to provide evidence of the metabolic profile in
response to prolonged ultramarathon running using an untargeted approach. The findings provide an
insight to the effects of ultramarathon running on the metabolic specificities and alterations that may
demonstrate cardio-protective effects.
4. Materials and Methods
4.1. Chemicals and Solvents
High-performance liquid chromatography (HPLC) grade Acetonitrile (ACN) was purchased
from Fisher Scientific (Loughborough, UK) and HPLC grade water was produced by a Direct-Q3
UltrapureWater System (Millipore, Watford, UK). AnalaR-grade formic acid (98%) was obtained
from BDH-Merck (Poole, UK). Authentic stock standard metabolites (Sigma-Aldrich, Poole, UK)
were prepared as previously described [61] and diluted four times with ACN LC-MS analysis of
the four mixtures of standards (Table S2). Mixtures of fatty acid standards were derived from the
hydrolysis of olive oil and cod liver oil with 1 M ethanolic KOH. These oils have well defined fatty
acid compositions [62]. Ammonium acetate was purchased from Sigma-Aldrich (Poole, UK).
4.2. Participants
Nine healthy trained male participants (mean ± SD) age 34 ± 7 years, .VO2max
61.6 ± 4.3 mL/min/kg, body mass 70.4 ± 6.6 kg, stature 178.3 ± 3 cm, body mass index 22.1
± 1.7 kg/m2 were voluntarily recruited and provided written informed consent. Ethical approval
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was obtained from Kingston University Faculty Ethics Committee and was conducted in accordance
to the declaration of Helsinki. All participants reported no illness or infection in the two weeks
leading up to the trial. Participants had on average 5.3 years’ (range 1–25 years) experience in
ultra-endurance exercise.
4.3. Experimental Design
The study was a cross-sectional observational time-trial conducted at Kingston University
London Human Performance Lab and all testing commenced at 07:00 ± 1:00 h. Food and drink
was provided ad libitum during the entire duration and self-selected according to the participants
preference to replicate habitual ultra-running conditions, but was not considered in the current analysis.
However, further analysis of food and fluid consumption may be warranted in further investigations.
Participants were asked to refrain from exercise and the consumption of alcohol 24 h prior to
commencement of the exercise trial, however were not required to be fasted to replicate habitual
ultra-marathon running conditions.
Plasma samples collected before (pre-80.5 km), and immediately after completion of the distance
(post-80.5 km) were analyzed for their metabolomic profiles using both HILIC and RPLC-MS methods.
4.4. Blood Sampling
Plasma samples were obtained from venous whole blood collected via venepuncture at rest
before commencement of the trial (pre-80.5 km) and on completion of the distance (post-80.5 km).
An additional 3 h fasted blood sample (baseline) was also collected at rest from all participants two
weeks prior to the 80.5 km trial. This was to enable comparison between baseline (B) and pre-80.5 km
(C) samples to validate that the changes seen were in response to the exercise trial (Supplementary
Materials Figures S1 and S2). Participants rested in a supine position for 10 min before blood sampling
at rest, and supine position immediately on completion of the trial. Blood samples were collected by
venepuncture from an antecubital vein of the forearm using EDTA vacutainers (Becton, Dickinson and
Company, Plymouth, UK). Blood samples were immediately centrifuged for 10 min at 2000 g at 4 ◦C
and plasma aliquots stored at −80 ◦C for subsequent analysis.
4.5. Sample Preparation
Exactly 100 µL of plasma was mixed with 400 µL of acetonitrile containing 5 µg/mL of 13C2
glycine (Sigma-Aldrich, Poole, UK) as an internal standard to ensure retention time stability, and then
centrifuged for 10 min before transferring into a vial with an insert. The pooled sample was prepared by
pipetting 50 µL from each of the 46 samples and then mixing them together before being diluting 0.2 mL
of the pooled sample with 0.8 mL of acetonitrile containing 5 µg/mL 13C2 glycine internal standard
followed by centrifuging. Additionally, the prepared mixtures of authentic standard metabolites [61]
containing 5 µg/mL of 13C2 glycine as internal standard were run.
4.6. LC-MS Conditions
Liquid chromatographic separation was carried out on an Accela HPLC system interfaced to
an Exactive Orbitrap mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) using both a
ZIC-pHILIC column (150× 4.6 mm, 5 µm, HiChrom, Reading, UK) and a reversed phase column (ACE
C4, 150 × 3.0 mm, 3 µm, HiChrom, Reading, UK). The metabolites were eluted from the ZICpHILIC
column with a mobile phase consisting of 20 mM ammonium carbonate in HPLC-grade water (solvent
A) and acetonitrile (solvent B), at a flow rate of 0.3 mL/min. The elution gradient was an A:B ratio
of 20:80 at 0 min, 80:20 at 30 min, 92:8 at 35 min and finally 20:80 at 45 min. The mobile phase for
elution of the ACE C4 column consisted of 1 mM acetic acid in water (A) and 1 mM acetic acid in
acetonitrile (B), at a flow rate of 0.4 mL/min. The elution gradient was as follows: A:B ratio 60:40
at 0 min, 0:100 at 30 min, 0:100 at 36 min, 60:40 at 37 min, 60:40 at 41 min. The nitrogen sheath and
auxiliary gas flow rates were maintained at 50 and 17 arbitrary units. The electrospray ionization (ESI)
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interface was operated in both positive and negative modes. The spray voltage was 4.5 kV for positive
mode and 4.0 kV for negative mode, while the ion transfer capillary temperature was 275 ◦C. Full scan
data were obtained in the mass-to-charge range of 75 to 1200 amu for both ionization modes. The MS
system fully calibrated prior to running according to manufacturer’s guidelines. The resulting data
were acquired using the XCalibur 2.1.0 software package (Thermo Fisher Scientific, Bremen, Germany).
The samples were run pairwise with two pooled samples being run at the beginning two after ten
samples and then two at the end.
4.7. Data Extraction and Analysis
The data was extracted by using MZ Match software (http://mzmatch.sourceforge.net/) [63]
and the identification of putative metabolites was made via the macro-enabled Excel file, Ideom
(http://mzmatch.sourceforge.net/ideom.html). The lists of the metabolites obtained from these
searches were then carefully evaluated manually by considering the quality of their peaks and their
retention time match with the standard metabolite mixtures run in the same sequence. All reported
metabolites were within 3 ppm of their exact masses. Statistical analyses were performed using both
univariate with Microsoft Excel and multivariate approaches using SIMCA-P software version 14.1
(Umetrics, Umea, Sweden). All subsequent metabolite responses were compared by paired t-test using
Microsoft Excel in order to indicate significant differences, where p < 0.05. Multivariate data analysis
was employed with SIMCA by fitting PCA-X models having refined the metabolite lists by removing
metabolites with RSD values >20% in the pooled samples.
5. Conclusions
The clearest impact of endurance exercise is on fatty acid metabolism but with respect to formation
of medium-chain unsaturated and partially oxidized fatty acids and conjugates of fatty acids with
carnitines. The most likely explanation for the complex pattern of medium-chain and oxidized fatty
acids formed is that the ultramarathon provoked the proliferation of peroxisomes. The peroxisomes
may serve two functions, one of providing a readily utilizable from of energy in the form of acetyl
carnitine and other acyl carnitines for export to mitochondria in the muscles, without the investment
of the ATP required to conjugate free fatty acids to CoA. Secondly the peroxisomes may serve to
regulate the levels of oxidized metabolites of long-chain fatty acids since many of these metabolites can
provoke biological responses such as vasoconstriction or have pro-inflammatory activity. This is the
first study using an untargeted metabolomics approach to determine the metabolic profile in response
to ultramarathon running. The findings provide an insight to the effects of ultramarathon distance
running on the metabolic specificities and alterations that may demonstrate cardio-protective effects.
Supplementary Materials: The following are available online at www.mdpi.com/2218-1989/8/1/14/s1. Figures
S1 and S2: Showing PCA Plots for baseline and pre-80.5 km samples. Figures S3–S80: Bar graphs for selected
metabolites comparing of pre- and post-80.5 km samples and baseline and pre-80.5 km samples. Figure S81:
Extracted ion traces for hydroxyoctadecadienoic acids in a pre-80.5 km sample and a post-80.5 km sample run on
an ACE C4 column. Table S1: showing metabolites annotated to MSI level 1. Table S2: A list of 231 metabolite
standards used to characterize the columns.
Acknowledgments: The authors thank all the ultramarathon runners who volunteered to participate in this
study. This study was supported by scholarship funding from Kingston University, London. We thank the Saudi
Government for a scholarship for AA.
Author Contributions: C.C.F.H., D.M., O.S., H.J.M. recruited the ultramarathon runners and took samples from
them. A.A. and D.G.W. prepared the plasma samples, ran them on the high-resolution mass spectrometry system
and processed the data. A.A., D.G.W., A.B.M., M.B., D.M., H.J.M., O.S. and C.C.F.H. contributed to the writing of
the manuscript and data interpretation.
Conflicts of Interest: The authors declare no conflict of interest.
Metabolites 2018, 8, 14 14 of 17
References
1. Harper, S.; Howse, K. An upper limit to human longevity? J. Popul. Ageing 2008, 1, 99–106. [CrossRef]
2. Williams, P.T. Relationship of distance run per week to coronary heart disease risk factors in 8283 male
runners: The national runners’ health study. Arch. Intern. Med. 1997, 157, 191–198. [CrossRef] [PubMed]
3. Trappe, S. Marathon runners. Sports Med. 2007, 37, 302–305. [CrossRef] [PubMed]
4. Faulkner, J.A.; Davis, C.S.; Mendias, C.L.; Brooks, S.V. The aging of elite male athletes: Age-related changes
in performance and skeletal muscle structure and function. Clin. J. Sport Med. 2008, 18, 501–507. [CrossRef]
[PubMed]
5. Sarris, J.; O’Neil, A.; Coulson, C.E.; Schweitzer, I.; Berk, M. Lifestyle medicine for depression. BMC Psychiatry
2014, 14, 107. [CrossRef] [PubMed]
6. World Health Organization. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control; World Health
Organization: Geneva, Switzerland, 2009.
7. Williams, P.T. Lower prevalence of hypertension, hypercholesterolemia, and diabetes in marathoners.
Med. Sci. Sports Exerc. 2009, 41, 523–529. [CrossRef] [PubMed]
8. Hoffman, M.D.; Krishnan, E. Exercise behavior of ultramarathon runners: Baseline findings from the
ultrastudy. J. Strength Cond. Res. 2013, 27, 2939–2945. [CrossRef] [PubMed]
9. O’keefe, J.H.; Patil, H.R.; Lavie, C.J.; Magalski, A.; Vogel, R.A.; McCullough, P.A. Potential adverse
cardiovascular effects from excessive endurance exercise. Mayo Clin. Proc. 2012, 87, 587–595. [CrossRef]
[PubMed]
10. Denham, J.; Nelson, C.P.; O’Brien, B.J.; Nankervis, S.A.; Denniff, M.; Harvey, J.T.; Marques, F.Z.; Codd, V.;
Zukowska-Szczechowska, E.; Samani, N.J. Longer leukocyte telomeres are associated with ultra-endurance
exercise independent of cardiovascular risk factors. PLoS ONE 2013, 8, e69377. [CrossRef] [PubMed]
11. Borghini, A.; Giardini, G.; Tonacci, A.; Mastorci, F.; Mercuri, A.; Sposta, S.M.; Moretti, S.; Andreassi, M.G.;
Pratali, L. Chronic and acute effects of endurance training on telomere length. Mutagenesis 2015, 30, 711–716.
[CrossRef] [PubMed]
12. Hoffman, M.D.; Ong, J.C.; Wang, G. Historical analysis of participation in 161 km ultramarathons in North
America. Int. J. Hist. Sport 2010, 27, 1877–1891. [CrossRef] [PubMed]
13. Cejka, N.; Rüst, C.A.; Lepers, R.; Onywera, V.; Rosemann, T.; Knechtle, B. Participation and performance
trends in 100-km ultra-marathons worldwide. J. Sports Sci. 2014, 32, 354–366. [CrossRef] [PubMed]
14. Krouse, R.Z.; Ransdell, L.B.; Lucas, S.M.; Pritchard, M.E. Motivation, goal orientation, coaching, and training
habits of women ultrarunners. J. Strength Cond. Res. 2011, 25, 2835–2842. [CrossRef] [PubMed]
15. Rochat, N.; Hauw, D.; Philippe, R.A.; von Roten, F.C.; Seifert, L. Comparison of vitality states of finishers and
withdrawers in trail running: An enactive and phenomenological perspective. PLoS ONE 2017, 12, e0173667.
[CrossRef] [PubMed]
16. Knechtle, B.; Rüst, C.A.; Rosemann, T.; Lepers, R. Age-related changes in 100-km ultra-marathon running
performance. Age 2012, 34, 1033–1045. [CrossRef] [PubMed]
17. Khodaee, M.; Spittler, J.; VanBaak, K.; Changstrom, B.; Hill, J. Effects of running an ultramarathon on cardiac,
hematologic, and metabolic biomarkers. Int. J. Sports Med. 2015, 94, 867–871. [CrossRef] [PubMed]
18. Shave, R.; Oxborough, D. Exercise-induced cardiac injury: Evidence from novel imaging techniques and
highly sensitive cardiac troponin assays. Prog. Cardiovasc. Dis. 2012, 54, 407–415. [CrossRef] [PubMed]
19. Simpson, D.; Post, P.G.; Young, G.; Jensen, P.R. “It’s not about taking the easy road”: The experiences of
ultramarathon runners. Sport Psychol. 2014, 28, 176–185. [CrossRef]
20. Pearson, H. Physiology: Freaks of nature? Nature 2006, 444, 1000–1001. [CrossRef] [PubMed]
21. Tanaka, H.; Seals, D.R. Endurance exercise performance in masters athletes: Age-associated changes and
underlying physiological mechanisms. J. Physiol. 2008, 586, 55–63. [CrossRef] [PubMed]
22. Noakes, T.D.; Lambert, E.V.; Lambert, M.I.; McArthur, P.S.; Myburgh, K.H.; Benade, A.S. Carbohydrate
ingestion and muscle glycogen depletion during marathon and ultramarathon racing. Eur. J. Appl. Physiol.
Occup. Physiol. 1988, 57, 482–489. [CrossRef] [PubMed]
Metabolites 2018, 8, 14 15 of 17
23. Ivy, J.L.; Goforth, H.W., Jr.; Damon, B.M.; McCauley, T.R.; Parsons, E.C.; Price, T.B. Early postexercise muscle
glycogen recovery is enhanced with a carbohydrate-protein supplement. J. Appl. Physiol. 2002, 93, 1337–1344.
[CrossRef] [PubMed]
24. Was´kiewicz, Z.; Kłapcin´ska, B.; Sadowska-Kre˛pa, E.; Czuba, M.; Kempa, K.; Kimsa, E.; Gerasimuk, D. Acute
metabolic responses to a 24-h ultra-marathon race in male amateur runners. Eur. J. Appl. Physiol. 2012, 112,
1679–1688. [CrossRef] [PubMed]
25. Muhsen Ali, A.; Burleigh, M.; Daskalaki, E.; Zhang, T.; Easton, C.; Watson, D.G. Metabolomic profiling of
submaximal exercise at a standardised relative intensity in healthy adults. Metabolites 2016, 6, 9. [CrossRef]
[PubMed]
26. Sparling, P.B.; O’donnell, E.M.; Snow, T.K. The gender difference in distance running performance has
plateaued: An analysis of world rankings from 1980 to 1996. Med. Sci. Sports Exerc. 1998, 30, 1725–1729.
[CrossRef] [PubMed]
27. Baker, A.B.; Tang, Y.Q. Aging performance for masters records in athletics, swimming, rowing, cycling,
triathlon, and weightlifting. Exp. Aging Res. 2010, 36, 453–477. [CrossRef] [PubMed]
28. Hunter, S.K.; Stevens, A.A.; Magennis, K.; Skelton, K.W.; Fauth, M. Is there a sex difference in the age of elite
marathon runners? Med. Sci. Sports Exerc. 2011, 43, 656–664. [CrossRef] [PubMed]
29. Ransdell, L.B.; Vener, J.; Huberty, J. Masters athletes: An analysis of running, swimming and cycling
performance by age and gender. J. Exerc. Sci. Fit. 2009, 7, S61–S73. [CrossRef]
30. Knechtle, B.; Wirth, A.; Knechtle, P.; Zimmermann, K.; Kohler, G. Personal best marathon performance is
associated with performance in a 24-h run and not anthropometry or training volume. Br. J. Sports Med.
2009, 43, 836–839. [CrossRef] [PubMed]
31. Lepers, R.; Cattagni, T. Do older athletes reach limits in their performance during marathon running? Age
2012, 34, 773–781. [CrossRef] [PubMed]
32. Daskalaki, E.; Easton, C.; Watson, D.G. The application of metabolomic profiling to the effects of physical
activity. Curr. Metab. 2014, 2, 233–263. [CrossRef]
33. Carnethon, M.R.; Gulati, M.; Greenland, P. Prevalence and cardiovascular disease correlates of low
cardiorespiratory fitness in adolescents and adults. JAMA 2005, 294, 2981–2988. [CrossRef] [PubMed]
34. Sumner, L.W.; Amberg, A.; Barrett, D.; Beale, M.H.; Beger, R.; Daykin, C.A.; Fan, T.W.-M.; Fiehn, O.;
Goodacre, R.; Griffin, J.L. Proposed minimum reporting standards for chemical analysis. Metabolomics 2007,
3, 211–221. [CrossRef] [PubMed]
35. Benjamini, Y.; Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to
multiple testing. J. R. Stat. Soc. Ser. B Methodol. 1995, 57, 289–300.
36. Neal, C.M.; Hunter, A.M.; Brennan, L.; O’Sullivan, A.; Hamilton, D.L.; DeVito, G.; Galloway, S.D. Six weeks
of a polarized training-intensity distribution leads to greater physiological and performance adaptations
than a threshold model in trained cyclists. J. Appl. Physiol. 2013, 114, 461–471. [CrossRef] [PubMed]
37. Lustgarten, M.S.; Price, L.L.; Logvinenko, T.; Hatzis, C.; Padukone, N.; Reo, N.V.; Phillips, E.M.; Kirn, D.;
Mills, J.; Fielding, R.A. Identification of serum analytes and metabolites associated with aerobic capacity.
Eur. J. Appl. Physiol. 2013, 113, 1311–1320. [CrossRef] [PubMed]
38. Huffman, K.M.; Koves, T.R.; Hubal, M.J.; Abouassi, H.; Beri, N.; Bateman, L.A.; Stevens, R.D.; Ilkayeva, O.R.;
Hoffman, E.P.; Muoio, D.M. Metabolite signatures of exercise training in human skeletal muscle relate
to mitochondrial remodelling and cardiometabolic fitness. Diabetologia 2014, 57, 2282–2295. [CrossRef]
[PubMed]
39. Xu, G.; Hansen, J.; Zhao, X.; Chen, S.; Hoene, M.; Wang, X.-L.; Clemmesen, J.O.; Secher, N.H.; Häring, H.;
Pedersen, B. Liver and muscle contribute differently to the plasma acylcarnitine pool during fasting and
exercise in humans. J. Clin. Endocrinol. Metab. 2016, 101, 5044–5052. [CrossRef] [PubMed]
40. Zhang, J.; Light, A.R.; Hoppel, C.L.; Campbell, C.; Chandler, C.J.; Burnett, D.J.; Souza, E.C.; Casazza, G.A.;
Hughen, R.W.; Keim, N.L. Acylcarnitines as markers of exercise-associated fuel partitioning, xenometabolism,
and potential signals to muscle afferent neurons. Exp. Physiol. 2017, 102, 48–69. [CrossRef] [PubMed]
Metabolites 2018, 8, 14 16 of 17
41. Volek, J.S.; Freidenreich, D.J.; Saenz, C.; Kunces, L.J.; Creighton, B.C.; Bartley, J.M.; Davitt, P.M.; Munoz, C.X.;
Anderson, J.M.; Maresh, C.M. Metabolic characteristics of keto-adapted ultra-endurance runners. Metabolism
2016, 65, 100–110. [CrossRef] [PubMed]
42. Ginsburg, G.S.; Agil, A.; O’toole, M.; Rimm, E.; Douglas, P.S.; Rifai, N. Effects of a single bout of
ultraendurance exercise on lipid levels and susceptibility of lipids to peroxidation in triathletes. JAMA 1996,
276, 221–225. [CrossRef] [PubMed]
43. Nieman, D.C.; Shanely, R.A.; Luo, B.; Meaney, M.P.; Dew, D.A.; Pappan, K.L. Metabolomics approach to
assessing plasma 13-and 9-hydroxy-octadecadienoic acid and linoleic acid metabolite responses to 75-km
cycling. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2014, 307, R68–R74. [CrossRef] [PubMed]
44. Nieman, D.C.; Meaney, M.P.; John, C.S.; Knagge, K.J.; Chen, H. 9-and 13-hydroxy-octadecadienoic acids (9 +
13 hode) are inversely related to granulocyte colony stimulating factor and il-6 in runners after 2 h running.
Brain Behav. Immun. 2016, 56, 246–252. [CrossRef] [PubMed]
45. Abeywardena, M.Y.; Head, R.J. Longchain n − 3 polyunsaturated fatty acids and blood vessel function.
Cardiovasc. Res. 2001, 52, 361–371. [CrossRef]
46. Turner, J.E.; Bennett, S.J.; Bosch, J.A.; Griffiths, H.R.; Aldred, S. Ultra-Endurance Exercise: Unanswered Questions
in Redox Biology and Immunology; Portland Press Limited: London, UK, 2014.
47. Yamada, H.; Umemoto, T.; Kakei, M.; Momomura, S.-I.; Kawakami, M.; Ishikawa, S.-E.; Hara, K.
Eicosapentaenoic acid shows anti-inflammatory effect via gpr120 in 3t3-l1 adipocytes and attenuates adipose
tissue inflammation in diet-induced obese mice. Nutr. Metab. 2017, 14, 33. [CrossRef] [PubMed]
48. Mrakic-Sposta, S.; Gussoni, M.; Moretti, S.; Pratali, L.; Giardini, G.; Tacchini, P.; Dellanoce, C.; Tonacci, A.;
Mastorci, F.; Borghini, A. Effects of mountain ultra-marathon running on ros production and oxidative
damage by micro-invasive analytic techniques. PLoS ONE 2015, 10, e0141780. [CrossRef] [PubMed]
49. Wanders, R.J.; Waterham, H.R. Biochemistry of mammalian peroxisomes revisited. Annu. Rev. Biochem. 2006,
75, 295–332. [CrossRef] [PubMed]
50. Zipper, J. Proliferation of myocardial peroxisomes caused by several agents and conditions. J. Mol.
Cell. Cardiol. 1997, 29, 149–161. [CrossRef] [PubMed]
51. Ramsay, R.R.; Zammit, V.A. Carnitine acyltransferases and their influence on CoA pools in health and
disease. Mol. Asp. Med. 2004, 25, 475–493. [CrossRef] [PubMed]
52. Reddy, J.K.; Mannaerts, G.P. Peroxisomal lipid metabolism. Annu. Rev. Nutr. 1994, 14, 343–370. [CrossRef]
[PubMed]
53. Thomas, A.W.; Davies, N.A.; Moir, H.; Watkeys, L.; Ruffino, J.S.; Isa, S.A.; Butcher, L.R.; Hughes, M.G.;
Morris, K.; Webb, R. Exercise-associated generation of pparγ ligands activates pparγ signaling events and
upregulates genes related to lipid metabolism. J. Appl. Physiol. 2012, 112, 806–815. [CrossRef] [PubMed]
54. Harber, M.P.; Crane, J.D.; Dickinson, J.M.; Jemiolo, B.; Raue, U.; Trappe, T.A.; Trappe, S.W. Protein synthesis
and the expression of growth-related genes are altered by running in human vastus lateralis and soleus
muscles. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009, 296, R708–R714. [CrossRef] [PubMed]
55. Walker, D.K.; Dickinson, J.M.; Timmerman, K.L.; Drummond, M.J.; Reidy, P.T.; Fry, C.S.; Gundermann, D.M.;
Rasmussen, B.B. Exercise, amino acids and aging in the control of human muscle protein synthesis. Med. Sci.
Sports Exerc. 2011, 43, 2249–2258. [CrossRef] [PubMed]
56. Gatti, R.; Cappellin, E.; Zecchin, B.; Antonelli, G.; Spinella, P.; Mantero, F.; De Palo, E.F. Urinary high
performance reverse phase chromatography cortisol and cortisone analyses before and at the end of a race in
elite cyclists. J. Chromatogr. B 2005, 824, 51–56. [CrossRef] [PubMed]
57. Dovio, A.; Roveda, E.; Sciolla, C.; Montaruli, A.; Raffaelli, A.; Saba, A.; Calogiuri, G.; De Francia, S.;
Borrione, P.; Salvadori, P. Intense physical exercise increases systemic 11β-hydroxysteroid dehydrogenase
type 1 activity in healthy adult subjects. Eur. J. Appl. Physiol. 2010, 108, 681–687. [CrossRef] [PubMed]
58. Zielin´ski, J.; Krasin´ska, B.; Kusy, K. Hypoxanthine as a predictor of performance in highly trained athletes.
Int. J. Sports Med. 2013, 34, 1079–1086. [CrossRef] [PubMed]
59. Stathis, C.G.; Carey, M.F.; Hayes, A.; Garnham, A.P.; Snow, R.J. Sprint training reduces urinary purine loss
following intense exercise in humans. Appl. Physiol. Nutr. Metab. 2006, 31, 702–708. [CrossRef] [PubMed]
60. Subudhi, A.W.; Davis, S.L.; Kipp, R.W.; Askew, E.W. Antioxidant status and oxidative stress in elite alpine
ski racers. Int. J. Sport Nutr. Exerc. Metab. 2001, 11, 32–41. [CrossRef] [PubMed]
Metabolites 2018, 8, 14 17 of 17
61. Zhang, R.; Watson, D.G.; Wang, L.; Westrop, G.D.; Coombs, G.H.; Zhang, T. Evaluation of mobile phase
characteristics on three zwitterionic columns in hydrophilic interaction liquid chromatography mode
for liquid chromatography-high resolution mass spectrometry based untargeted metabolite profiling of
leishmania parasites. J. Chromatogr. A 2014, 1362, 168–179. [CrossRef] [PubMed]
62. British Pharamacopoeia 2013; The Stationary Office: London, UK, 2012.
63. Scheltema, R.A.; Jankevics, A.; Jansen, R.C.; Swertz, M.A.; Breitling, R. Peakml/mzmatch: A file format,
Java library, R library, and tool-chain for mass spectrometry data analysis. Anal. Chem. 2011, 83, 2786–2793.
[CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
